Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chaihu nasal spray is a Traditional Chinese Medicine (TCM)-derived pharmaceutical candidate developed by researchers at Fudan University for the treatment of the common cold and fever. The formulation utilizes the volatile oils or active components, such as saikosaponins, extracted from Radix Bupleuri (Chaihu). It is designed for intranasal administration to provide rapid antipyretic and anti-inflammatory effects by facilitating absorption through the nasal mucosa, potentially bypassing first-pass metabolism and offering a faster onset of action compared to traditional oral TCM formulations. The drug aims to reduce body temperature and alleviate symptoms associated with upper respiratory tract infections through the modulation of inflammatory mediators.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chaihu nasal spray.